Next Article in Journal
Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals
Next Article in Special Issue
Metabolic Vulnerabilities in Multiple Myeloma
Previous Article in Journal
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies
Previous Article in Special Issue
Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo
 
 
Article

Article Versions Notes

Cancers 2022, 14(5), 1173; https://doi.org/10.3390/cancers14051173
Action Date Notes Link
article xml file uploaded 24 February 2022 12:24 CET Original file -
article xml uploaded. 24 February 2022 12:24 CET Update -
article pdf uploaded. 24 February 2022 12:24 CET Version of Record https://www.mdpi.com/2072-6694/14/5/1173/pdf-vor
article html file updated 24 February 2022 12:25 CET Original file -
article xml file uploaded 25 February 2022 02:37 CET Update -
article xml uploaded. 25 February 2022 02:37 CET Update https://www.mdpi.com/2072-6694/14/5/1173/xml
article pdf uploaded. 25 February 2022 02:37 CET Updated version of record https://www.mdpi.com/2072-6694/14/5/1173/pdf
article html file updated 25 February 2022 02:38 CET Update -
article html file updated 1 August 2022 02:31 CEST Update https://www.mdpi.com/2072-6694/14/5/1173/html
Back to TopTop